1 Nov, 2021 Alzheon to Present New Data from Ongoing Phase 2 Biomarker Trial of ALZ-801 Oral Tablet at Clinical Trials in Alzheimer’s Disease (CTAD) Conference alzheon2024-08-12T10:06:16-04:00November 1st, 2021|Tags: Press Release Tag| Read More
13 Sep, 2021 Alzheon to Present at H.C. Wainwright Annual Global Investment Conference on September 13, 2021 alzheon2024-08-12T09:32:26-04:00September 13th, 2021|Tags: Press Release Tag| Read More
13 Sep, 2021 Alzheon Appoints Adem Albayrak as Head of Operations and Earvin Liang, PhD, as Vice President of Clinical Development alzheon2024-08-26T11:01:08-04:00September 13th, 2021|Tags: Press Release Tag| Read More
23 Jun, 2021 Alzheon Completes Patient Enrollment in Phase 2 Biomarker Trial of ALZ-801 Oral Tablet in APOE4 Carriers with Alzheimer’s Disease alzheon2024-08-05T19:54:22-04:00June 23rd, 2021|Tags: Press Release Tag| Read More
23 Jun, 2021 Peer-Reviewed Scientific Publication Demonstrates Central Role of Neurotoxic Soluble Amyloid Oligomers in Driving Alzheimer’s Pathogenesis alzheon2024-08-12T10:14:03-04:00June 23rd, 2021|Tags: Press Release Tag| Read More
4 Jun, 2021 Alzheon Announces First Patient Dosed in APOLLOE4 Phase 3 Trial of Oral ALZ 801 in Patients with Early Alzheimer’s Disease alzheon2024-08-26T10:57:03-04:00June 4th, 2021|Tags: Press Release Tag| Read More
4 May, 2021 Alzheon Partners with Czech Institute of Organic Chemistry and Biochemistry to Develop First Alzheimer’s Diagnostic Assay for Measuring Neurotoxic Beta Amyloid Oligomers in Human Brain alzheon2024-08-26T11:01:41-04:00May 4th, 2021|Tags: Press Release Tag| Read More
9 Mar, 2021 Alzheon to Present at H.C. Wainwright Global Life Sciences Conference alzheon2024-08-26T11:02:06-04:00March 9th, 2021|Tags: Press Release Tag| Read More
9 Dec, 2020 Alzheon Announces New Research Showing Accelerated Hippocampus Atrophy in APOE4/4 Patients with Early Alzheimer’s Disease alzheon2024-08-26T11:00:13-04:00December 9th, 2020|Tags: Press Release Tag| Read More
